RECORDING: Professionals’ Conference – 23 June 2023
A recording of the Retina UK Professionals' Conference on 23 June 2023. The Conference was held at the University of Westminster, Marylebone Campus in London and online.
Search results
A recording of the Retina UK Professionals' Conference on 23 June 2023. The Conference was held at the University of Westminster, Marylebone Campus in London and online.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Retina UK has joined with more than 80 disability charities who have today written to the Chancellor calling for urgent support with the cost of living for disabled people.
Katerina joined the Retina UK team at the start of 2023 after hearing about the charity through her involvement in a research project at the University of Bath, where she works as an academic.
Have you ever been tempted to take part in the TCS London Marathon? In 2022 the TCS London Marathon raised £58.3 million for charity so it’s a vital source of income.
Whether you are a professional looking for practical information for yourself, or practical or emotional support for your clients, online, by phone or face-to-face, we're here to help. All of our services are free to access and offered in a range of accessible formats.
A guide for professionals. Retina UK is a national charity. We offer information and support to people affected by inherited sight loss to enable them to lead better lives today and fund medical research to accelerate the search for treatments for the future. We also support professionals working with them.
Our sight loss survey highlighted that you have a real appetite to get involved in representing the inherited sight loss community through activities like focus groups, surveys and research projects via the Retina UK Lived Experience Panel.
Prof Dominic Ffytche will provide an explanation of what Charles Bonnet Syndrome is, the science behind it, and share some potential coping strategies for people who experience visual hallucinations.
With all the interest in exciting gene and cell therapies for inherited sight loss, it’s easy to forget that more traditional drugs can also hold promise.